United States Ultomiris Drug Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Ultomiris (ravulizumab-cwvz) is a terminal complement inhibitor administered via intravenous infusion that received FDA approval in 2018 for PNH and later for aHUS, developed by Alexion Pharmaceuticals before its acquisition by AstraZeneca in 2021. The drug offers a significant pharmacokinetic advantage over its predecessor Soliris (eculizumab) by requiring dosing only every eight weeks versus every two weeks, reducing infusion burden for patients. The market's $5.1 billion valuation reflects global sales across approved indications, with North America representing the largest share due to established treatment protocols and broad insurance coverage.

• •Approved in the US in December 2018 for PNH and later for aHUS and other complement-mediated disorders
• •Administered every 8 weeks vs. every 2 weeks for predecessor therapy, offering meaningful patient quality-of-life improvement
• •Marketed by AstraZeneca following its $39 billion acquisition of Alexion Pharmaceuticals in 2021

The 26.58% annual growth rate is fueled by ongoing label expansion into additional complement-mediated diseases, increased screening and diagnosis of rare blood disorders in under-treated populations, and the drug's position as a premium first-line therapy. AstraZeneca's continued investment in real-world evidence programs and patient support infrastructure is broadening adoption among hematologists and nephrologists. Additionally, pipeline developments exploring subcutaneous formulations and pediatric indications are expected to widen the addressable patient pool.

• •Expanding FDA and EMA label indications into additional rare disease categories beyond PNH and aHUS
• •Rising disease awareness and improved diagnostic capabilities in emerging markets across Asia-Pacific and Latin America
• •Clinical and commercial advantages over earlier-generation complement inhibitors driving treatment-switch decisions

The market is segmented by indication (PNH, aHUS, and other complement-mediated disorders), route of administration (intravenous infusion with emerging interest in subcutaneous delivery), and payer type (commercial, Medicare, Medicaid, and government/private outside the US). Geographically, North America commands the largest revenue share, followed by Europe and then Asia-Pacific, where rising healthcare investment and increasing recognition of rare blood disorders are accelerating uptake.

• •North America dominates market share due to high drug pricing, extensive insurance coverage, and concentrated specialist provider networks
• •Europe represents the second-largest market, with varying reimbursement timelines across individual countries
• •Asia-Pacific is the fastest-growing region, driven by improving diagnosis rates, expanding healthcare infrastructure, and regulatory approvals in Japan, China, and key markets

What are the recent trends and outlook?

The market is trending toward earlier diagnosis through genetic screening programs, increased use of patient registries to support long-term outcomes research, and development of more convenient subcutaneous formulations currently in clinical evaluation. AstraZeneca's commercial strategy emphasizes expanding access in lower-income markets through adaptive licensing and tiered pricing models. Analysts project that continued indication expansion and geographic market penetration will sustain above-industry-average growth through the early 2030s, though long-term projections will increasingly depend on the competitive timeline for emerging therapies.

• •Subcutaneous formulation development underway, which could further simplify administration and reduce healthcare facility visit burden
• •Growing emphasis on real-world evidence and long-term safety data to support expanded payer coverage globally
• •Patent expiry events beginning in the late 2020s will likely introduce biosimilar competition and reshape pricing dynamics